

Affibody Highlights Progress Across Radiopharmaceutical Pipeline at EANM 2026

Stockholm, Sweden, October 14, 2026. Affibody AB ("Affibody") today announced a series of presentations at the 2026 Congress of the European Association of Nuclear Medicine (EANM), taking place October 17-21 in Vienna. The presentations span both clinical and preclinical research and include results from the ongoing Phase 1 study with the Radioligand Therapy (RLT) candidate ABY-271 in HER2-positive metastatic breast cancer, clinical data with the HER2 PET imaging agent tezatabep matraxetan, and preclinical findings with Affibody[®] molecules targeting B7-H3. Together, the presentations highlight the breadth of Affibody's capabilities across targeted RLTs and precision imaging.

"The wealth and diversity of results being presented at EANM, one of the world's leading congresses in nuclear medicine and theranostics, reflects both the potential of our Affibody[®] technology and the strength of our collaborations," said David Beijer, Chief Executive Officer of Affibody. "We are excited to see our science translate into meaningful advancements with the aim to address significant unmet needs in patients with hard-to-treat cancers."

Presentations

Title: A First-in-Human Phase 1 Trial Safety and Biodistribution of [¹⁷⁷Lu]Lu-ABY-271 in Subjects with HER2-Positive Metastatic Breast Cancer (NCT07081555)

Presenter: Joachim Feldwisch, Affibody

Session: C: Therapy Clinical Study - C1 Oncological Therapy Clinical Study - C16 Other Oncological Treatments

Format: e-Poster

Presentation ID: EP-0981

Title: Whole-body HER2 PET/CT reveals spatial heterogeneity of HER2 expression in advanced gastroesophageal adenocarcinoma.

Presenter: Antonios Tzortzakakis, Karolinska Institutet

Date and Time: October 18, 2026, 08:00 CEST

Session: Clinical Oncology Track: Gastro-Intestinal Malignancy

Format: Oral

Presentation ID: OP-035

Title: Standardization of image quality and activity quantification in a multi-centre PET imaging study (Ex-PET)

Presenter: Jakob Lagerstedt, Karolinska University Hospital

Date and Time: October 20, 2026, 16:45 CEST

Session: Cutting Edge Science Track: Physics Committee: Quantitative PET: Harmonisation and Robustness

Format: Oral

Presentation ID: OP-734

Title: Preclinical Evaluation of PNABased Affibody-mediated Pretargeting for targeting HER2: A direct comparison between Tb-161 and Lu-177

Presenter: Maryam Oroujeni, Uppsala University

Date and Time: October 18, 2026, 09:45 CEST

Session: M2M Track: TROP Session - Radiopharmaceutical Sciences Committee: ^{161}Tb vs ^{177}Lu , and The Winner Is...

Format: Oral

Presentation ID: OP-084

Title: Modular Molecular Design of B7H3Targeting Affibody Molecules for Radionuclide Therapy: Biodistribution-Driven Selection and Therapy

Presenter: Maryam Oroujeni, Uppsala University

Date and Time: October 20, 2026, 16:45 CEST

Session: Radiopharmaceutical Sciences Committee: Modern Approaches to Drug Development in Nuclear Medicine

Format: Oral e-Poster

Presentation ID: EPS-223

Title: HER2-Ex PET trial: A multicentre, prospective, open-label study using $[^{68}\text{Ga}]\text{Ga-ABY-025}$ PET-imaging to characterize HER2-expression and explore the therapy-predictive value for HER2 antibody-drug conjugates in patients with metastatic breast cancer.

Presenter: Anna Kistner, Karolinska Institutet

Session: B: Imaging Clinical Studies - B1 Oncological Imaging Clinical Study - B13 Breast

Format: e-Poster

Presentation ID: EP-0261

Title: In vitro evaluation of Affibody molecules targeting B7-H3 for radionuclide therapy of neuroblastoma

Presenter: Maryam Oroujeni, Uppsala University

Session: A: Preclinical and Translational Studies - A1 Medical Preclinical - A11 In Vitro Studies

Format: e-Poster

Presentation ID: EP-0003

Title: Optimized Affibody Molecule targeting B7-H3 immune checkpoint: Improved Tumor Targeting Properties in a Syngeneic MC38 Model

Presenter: Enrique Recasens Pérez-Vera, Uppsala University

Session: A: Preclinical and Translational Studies - A1 Medical Preclinical - A18 New

Radiopharmaceuticals - Therapy

Format: e-Poster

Presentation ID: EP-0171

Title: Feasibility of affibody-based pretargeted delivery of ^{225}Ac

Presenter: Vladimir Tolmachev, Uppsala University

Session: A: Preclinical and Translational Studies - A1 Medical Preclinical - A18 New

Radiopharmaceuticals - Therapy

Format: e-Poster

Presentation ID: EP-0161

Title: Biodistribution and dosimetry for PET imaging of HER2-receptor expression using [18F]-HER2 in metastatic breast cancer

Presenter: Ulrika Estenberg, Karolinska University Hospital

Session: B: Imaging Clinical Studies - B10 Dosimetry in Diagnostic Applications - B101 Dosimetry in Diagnostic Applications

Format: e-Poster

Presentation ID: EP-0617

View the EANM abstracts here: <https://eanm26.eanm.org/abstracts-book/>

About ABY-271

ABY-271 is a Radioligand Therapy (RLT) candidate aimed at tumor cells that express HER2, regardless of their location in the body. The project builds on previous clinical research insights from the development of the PET imaging agent tezatabep matraxetan (ABY-025), showing that the candidate substance can bind to HER2 independently of the tumor origin. ABY-271 with the radioisotope lutetium-177 emits therapeutic beta radiation, exerting irreversible damage to the cancer cells.

About tezatabep matraxetan

Tezatabep matraxetan (ABY-025) is a Gallium-68-labeled PET tracer candidate that aims to enable non-invasive visualization of HER2 expression in cancer patients. The high affinity and rapid clearance of tezatabep matraxetan from blood and normal organs allows HER2 assessment within hours.

About HER2

HER2 is a protein that is involved in cell growth. HER2 is overexpressed by some types of cancer cells, including breast, stomach, esophageal, ovarian, bladder, and pancreatic cancers. HER2 may cause cancer cells to grow more quickly and spread to other parts of the body and HER2-positive cancers are therefore considered more aggressive than HER2-negative cancers. However, they are much more likely to respond to treatments that target the HER2 protein. HER2-targeted therapies can remain effective even after multiple lines of treatment.

About B7-H3

B7-H3 (also known as CD276) is a cell surface immunomodulatory glycoprotein overexpressed by many different types of cancers, whereas its expression is low in most normal organs and tissues. This makes it a promising target for cancer therapies. B7-H3 inhibits tumor specific immune responses and promotes tumor cell proliferation and invasion. High B7-H3 expression is generally associated with poor prognosis.

About Affibody® molecules

Affibody® molecules are a novel drug class of small therapeutic proteins with characteristics surpassing monoclonal antibodies (mAbs) and antibody fragments. The company has created a large library consisting of more than ten billion Affibody® molecules, all with unique binding sites, from which binders to given targets are selected. Affibody® molecules are only 6 kDa in size.

They have demonstrated clinical benefit both as tumor-targeting moieties and as efficacious disease modifying agents in autoimmune indications by utilizing the inherent differentiated properties of the platform.

About Affibody

Affibody is a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs) designed to deliver highly selective tumor targeting across a wide range of cancers. Leveraging decades of innovation in Affibody® molecule discovery and engineering, together with deep understanding of the RLT field, the company is advancing a novel pipeline focused on oncology indications with high unmet medical need. Affibody's lead RLT candidate, ABY-271, is currently being evaluated in a first-in-human clinical study in HER2-positive metastatic breast cancer.

The Affibody® platform has also demonstrated clinical value in immunology and inflammation, with multiple programs being advanced through strategic partnerships.

Affibody's main shareholder, Patricia Industries, is a part of Investor AB.

Further information can be found at: www.affibody.com.

Disclaimer

This press release contains forward-looking statements. While Affibody consider the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by several hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.

Affibody Contact

David Bejker, CEO, +46 706 454 948
Peter Zerhouni, CFO and CBO, +46 706 420 044

Media Contact

Richard Hayhurst, 59° North Communications, +44 (0) 7711 8215727, richard.hayhurst@59north.bio



Press Release

14 October 2026 09:15:00 CEST

Attachments

[Affibody Highlights Progress Across Radiopharmaceutical Pipeline at EANM 2026](#)